These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 26730183

  • 1. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
    Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
    [Abstract] [Full Text] [Related]

  • 2. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 15; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 4. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017 Aug 15; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 5. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
    Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.
    Drugs R D; 2016 Jun 15; 16(2):217-27. PubMed ID: 27028749
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 15; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 7. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A, Jankowski M, Gross-Sondej I, Storman M, Nowobilski R, Bala MM.
    Cochrane Database Syst Rev; 2018 Aug 24; 8(8):CD012355. PubMed ID: 30141826
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Aug 24; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 9. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
    Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S.
    Chest; 2014 Dec 24; 146(6):1521-1530. PubMed ID: 25058845
    [Abstract] [Full Text] [Related]

  • 10. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 24; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 11. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep 29; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 13. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 14. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 25; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 15. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
    Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 25; 14():2849-2861. PubMed ID: 31839705
    [Abstract] [Full Text] [Related]

  • 16. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 25; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

  • 17. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
    Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.
    Adv Ther; 2017 Nov 25; 34(11):2518-2533. PubMed ID: 29094315
    [Abstract] [Full Text] [Related]

  • 18. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May 25; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 19. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
    Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.
    Adv Ther; 2018 Jan 25; 35(1):56-71. PubMed ID: 29313286
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.
    Eur Respir J; 2014 Mar 25; 43(3):763-72. PubMed ID: 24114969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.